CD19 and precursor B-cell acute lymphoblastic leukemia: The use of such targeted agents in pediatric KMT2A-r B-ALL marks a significant step towards the management of such high-risk leukemias (Figure 1). Furthermore, CD-19 directed chimeric antigen receptor T-cell (CAR T) therapy has been extensively evaluated in R/R pediatric B-ALL and tisagenlecleucel is an approved agent in this setting.